Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Stroke. 2017 Jun 6;48(7):1948–1956. doi: 10.1161/STROKEAHA.117.016474

Figure 2. Effect of MRE-269 on neurological function and body weight loss in aged rats subjected to transient MCAO.

Figure 2

The drug was given as detailed in the legend of Fig. 1, and neurobehavioral analyses and body weight measurement were performed at pre- and post-MCAO. The same animals were MRI-scanned at 48 h and at 21 days (data presented in Fig. 1). Delayed MRE-269 treatment significantly improved long-term neurological outcomes assessed by adhesive removal test (A) and rotarod (B) compared to the vehicle group from day 3 to day 21 after MCAO. C) Bar graphs showing body weight loss was continuously increased from 48 h to day 21 after MCAO in the vehicle group, but MRE-269 treatment significantly attenuated body weight loss after one week following MCAO. Data in panels A to C were expressed as mean ± SEM, *P<0.05, **P<0.01 and ***P<0.001 versus vehicle. Vehicle, n=8; MRE-269, n=9.